ArticleScientific reports2026
Uncovering the bactericidal potential of extract and multi-targeting phytochemicals from Mirabilis longiflora L. leaves against multidrug-resistant Pseudomonas aeruginosa and Bacillus cereus.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mirabilis longiflora L. has been used traditionally in some parts of Bangladesh for the treatment of headaches, infectious diseases, painkillers, skin disease, herpes infection, and wound healing, but its effects on multidrug-resistant (MDR) bacteria have remained unidentified. Therefore, we aimed to determine the antibacterial activity of the methanol extract of M. longiflora L. leaves (MEMLL) against MDR Pseudomonas aeruginosa and Bacillus cereus and to recognize possible multitargeting antibacterial phytocompounds through in silico computational approaches targeting the LasR and LpxC proteins in MDR Pseudomonas aeruginosa and the FosB and PlcR proteins in MDR Bacillus cereus. PPS, FT-IR, and GC-MS were used for profiling of the phytocompounds in MEMLL. The antimicrobial activity of MEMLL was evaluated using in vitro agar-well diffusion, MIC, and MBC assays. In silico methods were applied to identify multi-targeting agents from GC-MS-annotated phytocompounds. MEMLL showed dose-dependent antibacterial activity and exposed the presence of 33 phytochemicals in GC-MS analysis. Among these, 6-Hydroxy-4,4,7a-trimethyl-5,6,7,7a-tetrahydrobenzofuran-2(4 H)-one (CID 14334) was identified as a potential antibacterial phytocompound as it exhibited multi-modal and strong binding affinity towards LasR, LpxC, FosB, and PlcR, favorable pharmacokinetics, drug-likeness, physicochemical, and toxicity properties. Finally, Molecular dynamics (MD) simulations demonstrated the structural stability of CID 14,334 within the active sites of LasR, LpxC, FosB, and PlcR. The results of this study offer scientific validation for the traditional use of M. longiflora L. in bacterial infection-related diseases. It also suggests that 6-Hydroxy-4,4,7a-trimethyl-5,6,7,7a-tetrahydrobenzofuran-2(4 H)-one from M. longiflora L. might be responsible for the antibacterial activity and could act as a phytopharmacological lead for the development of LasR and LpxC inhibitors against MDR Pseudomonas aeruginosa and FosB and PlcR inhibitors against MDR Bacillus cereus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.